These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36364937)

  • 1. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.
    Volpe S; Lisco G; Fanelli M; Racaniello D; Colaianni V; Triggiani D; Donghia R; Crudele L; Rinaldi R; Sabbà C; Triggiani V; De Pergola G; Piazzolla G
    Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study.
    Volpe S; Lisco G; Fanelli M; Racaniello D; Colaianni V; Lavarra V; Triggiani D; Crudele L; Triggiani V; Sabbà C; De Pergola G; Piazzolla G
    Front Endocrinol (Lausanne); 2023; 14():1240263. PubMed ID: 37780624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-Weekly Semaglutide Induces an Early Improvement in Body Composition in Patients with Type 2 Diabetes: A 26-Week Prospective Real-Life Study.
    Volpe S; Lisco G; Racaniello D; Fanelli M; Colaianni V; Vozza A; Triggiani V; Sabbà C; Tortorella C; De Pergola G; Piazzolla G
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.
    Romero-Gómez M; Lawitz E; Shankar RR; Chaudhri E; Liu J; Lam RLH; Kaufman KD; Engel SS;
    J Hepatol; 2023 Oct; 79(4):888-897. PubMed ID: 37355043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice.
    Pantanetti P; Cangelosi G; Alberti S; Di Marco S; Michetti G; Cerasoli G; Di Giacinti M; Coacci S; Francucci N; Petrelli F; Ambrosio G; Grinta R
    Front Endocrinol (Lausanne); 2024; 15():1394506. PubMed ID: 39015186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semaglutide alters gut microbiota and improves NAFLD in db/db mice.
    Mao T; Zhang C; Yang S; Bi Y; Li M; Yu J
    Biochem Biophys Res Commun; 2024 May; 710():149882. PubMed ID: 38583231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.
    Flint A; Andersen G; Hockings P; Johansson L; Morsing A; Sundby Palle M; Vogl T; Loomba R; Plum-Mörschel L
    Aliment Pharmacol Ther; 2021 Nov; 54(9):1150-1161. PubMed ID: 34570916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.
    Carretero-Gómez J; Carrasco-Sánchez FJ; Fernández-Rodríguez JM; Casado-Escribano P; Miramontes-González JP; Seguí-Ripoll JM; Ena J; Arévalo-Lorido JC;
    Rev Clin Esp (Barc); 2023 Mar; 223(3):134-143. PubMed ID: 36549643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Scavo MP; Lisco G; Depalo N; Rizzi F; Volpe S; Arrè V; Carrieri L; Notarnicola M; De Nunzio V; Curri ML; De Pergola G; Piazzolla G; Giannelli G
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.
    Arai T; Atsukawa M; Tsubota A; Oikawa T; Tada T; Matsuura K; Ishikawa T; Abe H; Kato K; Morishita A; Tani J; Okubo T; Nagao M; Iwabu M; Iwakiri K
    Diabetes Obes Metab; 2024 Nov; 26(11):4958-4965. PubMed ID: 39223865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
    Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
    J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease.
    Nishimiya N; Tajima K; Imajo K; Kameda A; Yoshida E; Togashi Y; Aoki K; Inoue T; Nakajima A; Utsunomiya D; Terauchi Y
    Intern Med; 2021 Nov; 60(21):3391-3399. PubMed ID: 33994437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
    Newsome PN; Buchholtz K; Cusi K; Linder M; Okanoue T; Ratziu V; Sanyal AJ; Sejling AS; Harrison SA;
    N Engl J Med; 2021 Mar; 384(12):1113-1124. PubMed ID: 33185364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semaglutide May Alleviate Hepatic Steatosis in T2DM Combined with NFALD Mice via miR-5120/ABHD6.
    Li R; Ye Z; She D; Fang P; Zong G; Hu K; Kong D; Xu W; Li L; Zhou Y; Zhang K; Xue Y
    Drug Des Devel Ther; 2022; 16():3557-3572. PubMed ID: 36238196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.
    Newsome P; Francque S; Harrison S; Ratziu V; Van Gaal L; Calanna S; Hansen M; Linder M; Sanyal A
    Aliment Pharmacol Ther; 2019 Jul; 50(2):193-203. PubMed ID: 31246368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
    Gastaldelli A; Repetto E; Guja C; Hardy E; Han J; Jabbour SA; Ferrannini E
    Diabetes Obes Metab; 2020 Mar; 22(3):393-403. PubMed ID: 31692226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
    Soto-Catalán M; Opazo-Ríos L; Quiceno H; Lázaro I; Moreno JA; Gómez-Guerrero C; Egido J; Mas-Fontao S
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial.
    Della Pepa G; Russo M; Vitale M; Carli F; Vetrani C; Masulli M; Riccardi G; Vaccaro O; Gastaldelli A; Rivellese AA; Bozzetto L
    Diabetes Res Clin Pract; 2021 Aug; 178():108984. PubMed ID: 34311022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.